| Pfizer 'shows accelerating pipeline' | Posted on 01/10/2008 in Pharmaceutical Company Product News Pfizer has issued an update to its research and development pipeline, which it claims to be accelerating and showing major growth in late-stage clinical development.
It said its phase III cohort now includes 25 programmes, - up from 16 in the past six months - with additions in a number of key areas, including cancer and heart disease.
The company's total pipeline from phase I through registration now includes 114 programmes.
It said 31 programmes have advanced to the next stage of their development since the last update, while one was withdrawn from registration and 13 were discontinued.
Pfizer added 19 of the programmes that advanced were in areas reported to be high-potential, including Alzheimer's disease, diabetes, inflammation, pain, oncology and schizophrenia.
Martin Mackay, president of global research and development at Pfizer, said: "We are making significant operational improvements and driving our strategies to accelerate development, refocus investments and further improve execution, including trial design and cycle times."
He added the company is investing in areas with favourable markets and those with strong unmet medical need and an opportunity to progress medical science.
Last week, Pfizer and Grameen Health announced a new partnership with the goal of exploring sustainable healthcare delivery models for use in the developing world.Other news stories from 01/10/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
